ABOS

Acumen Pharmaceuticals

Company identity has not yet been verified

See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.

Follow company

1Trials in this database

2Recorded changes · last 12 months

Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source

Trial	Sponsor	Phase	Status	Primary completion
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)NCT06335173	Acumen Pharmaceuticals	Phase 2	Active not recruiting	2026-10Estimated

Latest recorded trial changes

A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

NCT06335173 · Acumen Pharmaceuticals

Posted 2025-10-27Enrollment · participant countRecorded edit

− Previous value

count: 540; type: ESTIMATED

+ Updated value

count: 542; type: ACTUAL

Check registry source

A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)

NCT06335173 · Acumen Pharmaceuticals

Posted 2025-10-27Participant count typeRecorded edit

− Previous value

Estimated

+ Updated value

Actual

Check registry source